Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

149 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients.
McKenney JM, Proctor JD, Harris S, Chinchili VM. McKenney JM, et al. JAMA. 1994 Mar 2;271(9):672-7. JAMA. 1994. PMID: 8309029 Clinical Trial.
Lovastatin: a new cholesterol-lowering agent.
McKenney JM. McKenney JM. Clin Pharm. 1988 Jan;7(1):21-36. Clin Pharm. 1988. PMID: 3278832 Review.
Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients.
McCorvey E Jr, Wright JT Jr, Culbert JP, McKenney JM, Proctor JD, Annett MP. McCorvey E Jr, et al. Among authors: mckenney jm. Clin Pharm. 1993 Apr;12(4):300-5. Clin Pharm. 1993. PMID: 8458181 Clinical Trial.
Analytic and clinical performance of two compact cholesterol-testing devices.
Volles DF, McKenney JM, Miller WG, Ruffen D, Zhang D. Volles DF, et al. Among authors: mckenney jm. Pharmacotherapy. 1998 Jan-Feb;18(1):184-92. Pharmacotherapy. 1998. PMID: 9469692
Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction.
McKenney J. McKenney J. Am J Cardiol. 2002 Nov 20;90(10B):8K-20K. doi: 10.1016/s0002-9149(02)02967-3. Am J Cardiol. 2002. PMID: 12467936
Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis.
Ballantyne CM, Pazzucconi F, Pintó X, Reckless JP, Stein E, McKenney J, Bortolini M, Chiang YT. Ballantyne CM, et al. Among authors: mckenney j. Clin Ther. 2001 Feb;23(2):177-92. doi: 10.1016/s0149-2918(01)80001-1. Clin Ther. 2001. PMID: 11293552 Clinical Trial.
Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia.
Ballantyne CM, McKenney J, Trippe BS. Ballantyne CM, et al. Among authors: mckenney j. Am J Cardiol. 2000 Oct 1;86(7):759-63. doi: 10.1016/s0002-9149(00)01076-6. Am J Cardiol. 2000. PMID: 11018196 Clinical Trial.
Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
Insull W Jr, Black D, Dujovne C, Hosking JD, Hunninghake D, Keilson L, Knopp R, McKenney J, Stein E, Troendle AJ. Insull W Jr, et al. Among authors: mckenney j. Arch Intern Med. 1994 Nov 14;154(21):2449-55. Arch Intern Med. 1994. PMID: 7979841 Clinical Trial.
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.
Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, Black D. Davidson M, et al. Among authors: mckenney j. Am J Cardiol. 1997 Jun 1;79(11):1475-81. doi: 10.1016/s0002-9149(97)00174-4. Am J Cardiol. 1997. PMID: 9185636 Clinical Trial.
Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
Guyton JR, Blazing MA, Hagar J, Kashyap ML, Knopp RH, McKenney JM, Nash DT, Nash SD. Guyton JR, et al. Among authors: mckenney jm. Arch Intern Med. 2000 Apr 24;160(8):1177-84. doi: 10.1001/archinte.160.8.1177. Arch Intern Med. 2000. PMID: 10789612 Clinical Trial.
149 results
Jump to page
Feedback